Prestige Consumer Healthcare Inc. (NYSE: PBH) delivered fourth-quarter fiscal 2024 earnings per share of $1.02, a 4.7% decline from the year-ago period's figure. The metric also missed the Zacks Consensus Estimate by 10.5%. GAAP EPS for the quarter was 98 cents, a significant improvement from the year-ago loss of $4.78 per share. For the full year, adjusted EPS was $4.21, flat year over year. Revenues Total revenues in the fiscal fourth quarter declined 3.1% year over year (down 2.9% on an organic basis) to $276.9 million and lagged the Zacks Consensus Estimate by 3.5%. The disappointing revenue performance for the quarter was caused by supply chain pressure late in the fourth quarter that affected Prestige Consumer's ability to fulfill retailer orders. Full-year revenues were $1.13 billion, unchanged from the fiscal 2023 level. Segments in Detail The company conducts its operations through two reportable segments — North American OTC Healthcare and International OTC Healthcare. Revenues in the North American OTC Healthcare segment totaled $231.1 million, down 4.6% from the year-earlier quarter. Our model projected the segment's revenues to be $242.6 million in the fourth quarter. The revenue performance for the quarter was due to the inability to supply customer orders late in the quarter in certain brands as well as a lower Women's Health category and the strategic exit of private label business. Revenues in the International OTC Healthcare segment were $45.9 million, up 5.3% from the year-ago quarter's figure. The company reported strong performance across numerous brands and geographies. However, this was marred by poor supply chain constraints. Our model projected revenues from this segment to be $44.4 million. Prestige Consumer Healthcare Inc. Price, Consensus ...